Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China SXT PharmaceuticalsSTU:2RY1 47 EV-to-FCF is 4.68 as of Jul. 14, 2026, which is 4% below its 10-year median of 4.87. GuruFocus rates STU:2RY1 with a GF Score™ of 47/100 and a GF Value™ of €307.50. The stock has 7 warning signs investors should review. Among 562 Drug Manufacturers companies, China SXT Pharmaceuticals ranks worse than 177935.77% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, China SXT Pharmaceuticals's Enterprise Value is €-16.16 Mil.
China SXT Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.45 Mil. Therefore, China SXT Pharmaceuticals's EV-to-FCF for today is 4.68.
The historical rank and industry rank for China SXT Pharmaceuticals's EV-to-FCF or its related term are showing as below:
STU:2RY1'
s EV-to-FCF Range Over the Past 10 Years
Min: -17.62 Med: 4.87 Max: 7.29
Current: -17.62
During the past 10 years, the highest EV-to-FCF of China SXT Pharmaceuticals was 7.29. The lowest was -17.62. And the median was 4.87.
STU:2RY1's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.955
vs STU:2RY1: -17.62
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China SXT Pharmaceuticals (STU:2RY1) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China SXT Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
China SXT Pharmaceuticals's share price for today is €384.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China SXT Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-7.668.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
China SXT Pharmaceuticals EV-to-FCF Related Terms
China SXT Pharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2RY1 vs CABR, BFRI, BIOE: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's EV-to-FCF falls into.
China SXT Pharmaceuticals's current Enterprise Value is €-16.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China SXT Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals (STU:2RY1) has a EV-to-FCF of 4.68 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China SXT Pharmaceuticals and its competitors. This is near median its historical median of 4.87. According to the industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is China SXT Pharmaceuticals' EV-to-FCF too high?
China SXT Pharmaceuticals' current EV-to-FCF of 4.68 is near median its 10-year median of 4.87. The Drug Manufacturers industry median EV-to-FCF is 20.96. China SXT Pharmaceuticals' value of 4.68 is 77.7% below this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' EV-to-FCF compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 562 companies for EV-to-FCF. This places China SXT Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 20.96. China SXT Pharmaceuticals' value of 4.68 is 77.7% below this benchmark. While the company's 10-year median is 4.87 vs. the industry median of 20.96, China SXT Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current EV-to-FCF of 4.68 is 77.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current EV-to-FCF is 4.68, which is near median its own 10-year median of 4.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (STU:2RY1) has a current EV-to-FCF of 4.68. The stock's GF Value™ is €307.50, compared to a current price of €384.00 — trading 24.9% above its estimated fair value. The current EV-to-FCF is 4.68, which is near median its 10-year median of 4.87 and 77.7% below the Drug Manufacturers industry median of 20.96. China SXT Pharmaceuticals' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For China SXT Pharmaceuticals (STU:2RY1), the current EV-to-FCF is 4.68 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (STU:2RY1) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be overvalued.
The current stock price of €384.00 is trading 24.9% above its estimated GF Value™ of €307.50.
Key valuation signals for STU:2RY1:
EV-to-FCF: 4.68 (near median its 10-year median of 4.87)
GF Value™: €307.50 vs. price of €384.00 (24.9% above fair value)
Industry Position: 77.7% below the Drug Manufacturers median (#999999 of 562)
No single metric tells the full story. See the STU:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
47GF Score
Get the complete analysis for STU:2RY1
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RY1 has been successfully added to your 
